Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest MultiCell Technologies Inc. Stories

2012-08-10 02:22:59

WOONSOCKET, R.I., Aug. 10, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce the updated preclinical research results for MCT-465 and MCT-485. MCT-485 showed in vitro dose-effect cytotoxicity on several human hepatocellular carcinoma cell lines. MCT-485 induced robust TNFalpha and some IL-6 expression. In contrast, MCT-465 showed no cytotoxicity or anti-proliferative effect. The research results support further mechanistic and in vivo...

2012-05-16 02:29:32

WOONSOCKET, R.I., May 16, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce representatives from the Company will present preclinical research findings for MCT-465 and MCT-485 at CIMT 2012 (http://meeting.cimt.eu), Europe's largest meeting dedicated to cancer immunotherapy research and development. CIMT 2012 will be held in May 23-25 in Mainz, Germany. The title of the poster presentation is: "Sharply discordant biological properties of...

2012-02-16 07:30:00

WOONSOCKET, R.I., Feb. 16, 2012 /PRNewswire/ -- Xenogenics Corporation, a subsidiary of MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has exclusive license rights to a polyanhydride compounds drug delivery patent recently granted in Canada. The patent was granted to Rutgers University this July for polyanhydrides which link low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure into polymeric drug...

2012-01-03 07:30:00

WOONSOCKET, R.I., Jan. 3, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has received the final cash grant award payment of $303,102 under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program. The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act, and provides a tax credit or cash grant equal to eligible costs and expenses. To be eligible, a therapeutic development project must:...

2011-07-11 07:30:00

WOONSOCKET, R.I., July 11, 2011 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ("MultiCell") today announced that it entered into a sponsored research agreement with University Health Network pursuant to which Anand Ghanekar, M.D., Ph.D., of the University Health Network's Toronto General Hospital, will direct research activities relating to the evaluation of MultiCell's product candidates MCT-465 and MCT-485, in in vitro models for the treatment of primary liver...

2011-05-31 07:30:00

WOONSOCKET, R.I., May 31, 2011 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce the issuance of U.S. patent 7,935,528 by the United States Patent and Trademark Office (USPTO) relating to the isolation and use of human liver stem cells to treat liver disease. Under the terms of its license agreement with Rhode Island Hospital, MultiCell Technologies is the worldwide exclusive licensee of U.S. patent 7,935,528. The patent describes methods to...

2011-02-23 09:22:00

WOONSOCKET, R.I., Feb. 23, 2011 /PRNewswire/ -- Xenogenics Corporation ("Xenogenics"), a majority owned subsidiary of MultiCell Technologies, Inc. (OTC Bulletin Board MCET), is pleased to announce it has retained the Emmes Group to assist with the development and execution of its capital formation strategy to help finance expanded human clinical trials of its Ideal BioStent(TM). In animal testing and initial human use, the Ideal BioStent(TM) demonstrated equivalence in safety, short-term...

2010-11-02 07:00:00

WOONSOCKET, R.I., Nov. 2, 2010 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) announces it has received cash grant awards under the U.S. government's Qualifying Therapeutic Discovery Project ("QTDP") program. The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act, and provides a tax credit or grant equal to eligible costs and expenses for tax years 2009 and 2010. To be eligible, a therapeutic development project...

2010-10-19 07:00:00

WOONSOCKET, R.I., Oct. 19 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal(TM) BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property...

2010-08-02 07:00:00

WOONSOCKET, R.I., Aug. 2 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announces it has submitted four separate grant applications under the U.S. government's Qualifying Therapeutic Discovery Project ("QTDP"). The QTDP was created by Congress as part of the Patient Protection and Affordable Care Act, and provides a tax credit or grant equal to eligible costs and expenses for tax years 2009 and 2010. The Company submitted grant applications for its...